Comparative Pharmacology
Head-to-head clinical analysis: RENO 60 versus RENOVUE DIP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENO 60 versus RENOVUE DIP.
RENO-60 vs RENOVUE-DIP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RENO-60 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolality iodinated contrast agent. It attenuates X-rays by blocking photons due to the high atomic number of iodine, thereby enhancing vascular and tissue contrast. It distributes in extracellular fluid and is excreted unchanged by glomerular filtration.
RENOVUE-DIP is a radiocontrast agent, not a drug with pharmacological activity. It is a diagnostic agent that contains diatrizoate meglumine and diatrizoate sodium, which are ionic iodinated compounds. They work by attenuating X-rays, providing contrast in imaging studies. The mechanism is physical rather than pharmacological, increasing the radiodensity of vascular structures and tissues.
Intravenous administration of 0.5-1.0 mL/kg (up to 150 mL total) per radiographic procedure. Dose may be repeated once if needed.
5 mg orally once daily for hypertension; 2.5 mg orally once daily for diabetic nephropathy.
None Documented
None Documented
Terminal elimination half-life approximately 30-60 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Terminal half-life: 2.5 hours (range 2–3 hours); clinically, dosing interval is every 4 hours due to slow redistribution from effect site.
Primarily renal excretion via glomerular filtration; up to 20% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%).
Renal: 95% (60% unchanged, 35% as major metabolite); Biliary/Fecal: 5% as conjugates.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent